Ascendis Pharma A (ASND) Invested Capital (2021 - 2026)

Ascendis Pharma A has reported Invested Capital for 7 years, with the latest figure at $864.8 million in Q1 2026.

• Quarterly Invested Capital fell 25.94% year-over-year to $864.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 4.63% YoY) and the FY2025 annual result came in at $1.0 billion, up 10.86% from the prior year.
• Invested Capital declined to $864.8 million in Q1 2026 per ASND's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Invested Capital peaked at $1.3 billion in Q3 2025 and troughed at $20.3 million in Q3 2022.
• A 5-year average of $761.2 million and a median of $834.6 million in 2023 frame the typical range for Invested Capital.
• The widest YoY moves for Invested Capital: up 4018.94% in 2023, down 96.46% in 2023.
• Over 5 years, Invested Capital stood at $518.7 million in 2022, then surged by 33.65% to $693.2 million in 2023, then jumped by 32.05% to $915.4 million in 2024, then advanced by 10.86% to $1.0 billion in 2025, then decreased by 14.78% to $864.8 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $864.8 million, $1.0 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.